search
Back to results

Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study (DEEP)

Primary Purpose

Diabetes Mellitus, Type 1, Pediatric ALL

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Monitoring of the patients
Sponsored by
ISIS Diabete Service
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Diabetes Mellitus, Type 1

Eligibility Criteria

12 Months - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children (<18 yo) with not controlled type 1 diabetes seen by diabetologists/paediatricians immediately following the initiation of CSII.
  • Children for whom it is the first initiation of CSII.
  • Children (or their parents if necessary) having read the information note and having dated and signed the informed consent form.

Exclusion Criteria:

  • Children with a history of diabetes less than 12 months.
  • Children with HbA1c values below 7.5 or above 10 before CSII initiation.
  • Children treated by CSII for more than 3 months.

Sites / Locations

  • Isis Diabete ServiceRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Standard monitoring

Intensive monitoring

Arm Description

Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls. Standard technical training, maintenance and monitoring by the CSII service provider as defined by the official specifications (LPPR)

Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls completed by a personalized vision of the patient glycaemic data along the study. Intensive technical training, maintenance and monitoring by the CSII service provider with a higher frequency of contacts during the period (additional nurse visits).

Outcomes

Primary Outcome Measures

Impact on glycaemic control one year after CSII initiation
Evolution of HbA1c measurement between last measure before CSII initiation and 12 months after.
Impact on glycaemic control all along the study
Unplanned hospitalization rate during the study Severe hypoglycemia during the study period

Secondary Outcome Measures

Impact on glycaemic control upon age classes
sub-groups based one age (<7 years old [yo], 7-12 yo, 13-17 yo)

Full Information

First Posted
September 20, 2019
Last Updated
December 3, 2020
Sponsor
ISIS Diabete Service
search

1. Study Identification

Unique Protocol Identification Number
NCT04100070
Brief Title
Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study
Acronym
DEEP
Official Title
Impact of an Intensive Monitoring on Glycaemic Control One Year After Initiating Continuous Subcutaneous Insulin Infusion in Children With Type 1 Diabetes.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 2, 2019 (Actual)
Primary Completion Date
October 31, 2021 (Anticipated)
Study Completion Date
December 31, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ISIS Diabete Service

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
More than half of type 1 diabetes (DT1) children are under CSII (Continuous Subcutaneous Insulin Infusion). Several studies showed that despite a patients' follow-up mostly by hospital-based paediatricians, there are still some concerns on long-term glycaemic control with inconstant results on glycaemic control either due to CSII adherence or nutrition management issues. Consequently, this real life study aims to compare two monitoring methods (standard versus intensive) in children initiating a CSII treatment and assess the impact on glycaemic control after one year.
Detailed Description
As CSII becomes more and more the gold standard therapy in children with type 1 diabetes, there have been some questions regarding the long-term effect of these treatments with some concerns on the inconstant results on glycaemic control either due to CSII adherence or nutrition management issues. The DCCT (Diabetes Control and Complications Trial) study has already shown in diabetic adults that intensification of treatment and follow-up could result in significative improvement of glycaemic control. This study aims to test this hypothesis of significant improvement after one year following CSII initiation on glycaemic control. Two parallel arms will be compared in real life conditions; one with standard recommendations-based follow-up by both diabetologists/pediatricians and service provider and the other with intensive follow-up with higher frequency of provider's nurses visits and personalization of patient status transferred to the physician for each diabetologists/pediatricians visit. Thus, investigators could determine after one year if the glycaemic control is better with one or the other of these follow-up procedures. Glycaemic control will be assessed both by the evolution of HbA1c during the study period and its last level at the end of the study. Its evaluation will be completed by counting of all symptomatic hypoglycemia occurence during the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1, Pediatric ALL

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective randomized parallel groups open study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
320 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard monitoring
Arm Type
Other
Arm Description
Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls. Standard technical training, maintenance and monitoring by the CSII service provider as defined by the official specifications (LPPR)
Arm Title
Intensive monitoring
Arm Type
Other
Arm Description
Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls completed by a personalized vision of the patient glycaemic data along the study. Intensive technical training, maintenance and monitoring by the CSII service provider with a higher frequency of contacts during the period (additional nurse visits).
Intervention Type
Behavioral
Intervention Name(s)
Monitoring of the patients
Intervention Description
Follow-up of the patients during the 12 months study periods including : visits with the diabetologist/pediatrician contacts with the service provider (nurses' visits) (more in intensive group) personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)
Primary Outcome Measure Information:
Title
Impact on glycaemic control one year after CSII initiation
Description
Evolution of HbA1c measurement between last measure before CSII initiation and 12 months after.
Time Frame
HbA1c values at inclusion and last known measurement at the 12 months last visit
Title
Impact on glycaemic control all along the study
Description
Unplanned hospitalization rate during the study Severe hypoglycemia during the study period
Time Frame
Assessment and counting of all unplanned hospitalizations during the 12 months period
Secondary Outcome Measure Information:
Title
Impact on glycaemic control upon age classes
Description
sub-groups based one age (<7 years old [yo], 7-12 yo, 13-17 yo)
Time Frame
HbA1c values at inclusion and last known measurement at the 12 months last visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Months
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children (<18 yo) with not controlled type 1 diabetes seen by diabetologists/paediatricians immediately following the initiation of CSII. Children for whom it is the first initiation of CSII. Children (or their parents if necessary) having read the information note and having dated and signed the informed consent form. Exclusion Criteria: Children with a history of diabetes less than 12 months. Children with HbA1c values below 7.5 or above 10 before CSII initiation. Children treated by CSII for more than 3 months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Arnaud Jerome, PhD
Phone
00 (33) 6 19 85 67 07
Email
arnaud.jerome@isisdiabete.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Alix Geissler, PhD
Phone
00 (33) 6 17 41 0291
Email
alix.geissler@isisdiabete.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc Nicolino, MD PhD
Organizational Affiliation
Hospices Civils de Lyon
Official's Role
Principal Investigator
Facility Information:
Facility Name
Isis Diabete Service
City
Gennevilliers
State/Province
Ile De France
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arnaud Jerome, PhD
First Name & Middle Initial & Last Name & Degree
Alix Geissler
First Name & Middle Initial & Last Name & Degree
Marc Nicolino, MD PhD
First Name & Middle Initial & Last Name & Degree
Claire Le Tallec, MD PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study

We'll reach out to this number within 24 hrs